CASI Pharmaceuticals
CASI
CASI was delisted on the 25th of February, 2026.
1 hedge funds and large institutions have $17 invested in CASI Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 1 funds opening new positions, 0 increasing their positions, reducing their positions, and 1 closing their positions.
0% more funds holding
Funds holding: 1 → 1 (0)
0% less ownership
Funds ownership: 0% → 0% (-0%)
0% more first-time investments, than exits
New positions opened: 1 | Existing positions closed: 1
32% less capital inflows, than outflows
Capital inflows: $17 | Capital outflows: $25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
WPA
West Paces Advisors
Atlanta,
Georgia
|
+$17 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Simplex Trading
Chicago,
Illinois
|
-$25 |
CASI Hedge Fund Activity: Q2 2026 in Review
1 of the 8,355 institutional investors tracked by Wall St. Rank reported a position in CASI Pharmaceuticals (CASI) for Q2 2026, worth a combined $17 — down 32% from $25 a quarter earlier.
Fund positioning in CASI was balanced in Q2 2026: 1 fund opened new positions, 1 closed out, 0 added to existing stakes and 0 trimmed.
The largest buyer was West Paces Advisors, opening a new position worth an estimated $17. The largest seller was Simplex Trading, exiting entirely with an estimated $25 sold.
- 1 institutional investor held CASI Pharmaceuticals (CASI) as of Q2 2026, unchanged from Q1 2026.
- Funds reported $17 of CASI Pharmaceuticals stock for Q2 2026, down 32% quarter-over-quarter.
- 1 fund opened new CASI Pharmaceuticals positions in Q2 2026 and 1 closed out, a net change of 0 holders.
- The largest CASI Pharmaceuticals buyer in Q2 2026 was West Paces Advisors, an estimated $17 added.
- The largest CASI Pharmaceuticals seller in Q2 2026 was Simplex Trading, an estimated $25 sold.
Based on aggregated 13F filings for Q2 2026.